• Influenza vaccination should be given during influenza season only (approximately October to March in the Northern Hemisphere and approximately April through September in the Southern Hemisphere). Participants must agree not to receive live, attenuated influenza vaccine (e.g., FluMist®) within 28 days prior to the start of study treatment, during treatment, or within 90 days after the last dose of atezolizumab.